Recently, a recruitment information has attracted the attention of the venture capital circle. After a series of storms, Shenzhen veteran venture capital institution gaotejia has also joined the recruitment army of spring institutions recently. The “Recruitment” plan covers investment managers, postdoctoral, risk control managers and IR managers. It is noteworthy that, The emphasis of the recruitment information is to help entrepreneurs achieve great undertakings and create a new future of China’s medical and health industry with focus and hard work.
In the past 2021, despite the volatile market environment, according to the information disclosed by sun Jialin, general manager of gaotejia investment at the summary meeting, gaotejia medical and health industry phase V fund was established as scheduled, 15 high-quality project investments and 3 successful IPOs were completed throughout the year, and 9 projects have been declared or accepted, and the withdrawal amount throughout the year reached a record high.
old pe institutions start again
As an old pe institution growing up in Shenzhen, gaotejia investment has been established since 2001. It focuses on the investment in medical and health industry, takes strategic equity investment as the leading, and covers the whole stage of M & A, PE, VC, angel and so on. Since its establishment for more than 20 years, it has invested in Boya Bio-Pharmaceutical Group Co.Ltd(300294) , Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) , kangfang biology, Beijing Hotgen Biotech Co.Ltd(688068) , Sansure Biotech Inc(688289) and other well-known companies in the industry.
In 2022, the pace of gaotejia’s investment has also accelerated. According to the information disclosed on its official website, several financing information has been disclosed in January alone, including: gaotejia jointly led the c-round financing of Jiangsu new element medicine to continuously accelerate the R & D of innovative drugs for metabolic diseases; To accelerate the globalization of new ophthalmic drug R & D and the international distribution of Topnotch ophthalmic pharmaceutical enterprises; The company Lianying medical, which participated in two rounds of investment in 2018 and 2020, was also accepted for the IPO of the science and innovation board in January.
“We have been continuously recruiting people and will have a greater layout in the country in the future.” According to insiders of gaotejia. According to the reporter, this is a new deployment of gaotejia after its own 2.0 upgrade and evolution. Perhaps it is just a prelude to “starting again” from the beginning of recruitment. Focus and hard work have become gaotejia’s new corporate culture, which is inseparable from the resume of the new leader from industrial background.
The reporter saw on gaotejia’s official website that Bian Zhuang is the chairman of gaotejia’s team. Statistics show that Mr. Bian Zhuang is an active explorer and outstanding representative of the “Suzhou model” after China’s reform and opening up. He has successively held important management positions such as deputy director of Suzhou Light Industry Bureau, general manager of Suzhou Aipu electric appliance and chairman of Suzhou Aipu group.
The everfount CEO Sun Jialin, CFO Tan Guiling and executive partner Wang Haijiao in the core management team are senior staff members of Gao Jia Jia, and other partners have new faces. By recruiting professional investment talents, fresh blood is still flowing to this local venture capital in Shenzhen.
Some people in the industry once worried that the industry resources accumulated for many years would dissipate due to the contradictions within the company. Some institutions that once grew up side by side with gaotejia lamented that a good investment brand growing up in Shenzhen would disappear. However, the “inside story” of gaotejia, which has experienced wind and rain, is still there, with an asset management scale of more than 20 billion yuan, 25 medical and health industry funds (including USD funds), and has successively invested in more than 150 enterprises (including more than 80 medical and health enterprises), which has promoted the successful listing of 31 enterprises.
Through the external voice, we can see the new faces of the old institutions. Gaotejia still has one of the largest professional medical investment teams in China, and its goal is more clear: to build an ecological platform for medical and health industry investment and strive to become a medical and health investment institution with global influence.
new investment method in gaotejia 2.0 era
Although the company has been affected by a series of storms in the past few years, gaotejia, who has entered the new era of 2.0, seems to be using actions to prove that the new playing method is gradually playing a role. “New thinking, new planning and new measures” run through every public voice of gaotejia.
In order to focus on the technological frontier, explore the future of the industry and adhere to the decision-making logic of research driven investment, Gao Jian, an industry research special publication disclosed on the official website, shares the latest hot spots and research trends of the industry.
“Leading the investment direction with research is the mature methodology established by gaotejia in the field of medical and health care.” Sun Jialin, general manager of gaotejia investment, said, “The medical and health industry has many subdivided fields, and its development stages and market-oriented paths are also different. How to dig out valuable subdivided tracks and investment targets in complex and diverse fields is the common proposition of every investment institution. Our investment research department and postdoctoral base were born under this background, and after years of accumulation, we have We have completed a complete industry wide map, gradually focused on a few key areas, truly grasped future investment opportunities and guided our investment direction. “
Zhao Xiaoyang, executive partner of gaotejia investment, believes that investment research in the field of medical and health must be supported by professional cognition, guided by clinical needs and based on industrial development. At the same time, it is comprehensively judged by combining a series of factors such as policy orientation, business model, scientific and technological innovation and payment reform. By building a high-level multi background team, optimizing the talent structure, further improving the investment and research ability, we incubate and invest in excellent medical and health enterprises all over the world, so as to create greater value for investors and contribute to the vigorous development of China’s medical and health undertakings.
In more subdivided fields, different partners also have research, such as the clinical mass spectrometry detection industry. Wang Haijiao believes that it is still in the early stage and is optimistic about the investment value in the detection service field within 3-5 years. In the long run, after the expansion of user base and application scenarios, it is a good time to invest in clinical mass spectrometry detection products.
Teng Yuhang, the investment partner of Jiangsu’s new element medicine, is a gouty investment executive partner. Gouty is a high concern area of high tech. Its high incidence rate and large market demand, but the safe and effective drugs are relatively limited. There are quite a lot of gout patients in the world who can not control the blood uric acid with reasonable risk benefit. The market urgently needs new drugs to make up for this deficiency.
“Considering that gout is a chronic disease requiring long-term medication, the consideration of side effects should be matched with diabetes drugs. Therefore, the safety of drugs is a major concern in our field of investigation.” Teng Yuhang said, “the core team of new element has been deeply engaged in the field of metabolic diseases for many years. The company’s core product abp-671 has shown obvious excellent safety and effectiveness data in clinical trials, which gives us sufficient confidence to support the rapid promotion of the product in the future, so as to realize its commercialization earlier and benefit gout patients.”
